Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	6.910 $	+0.88%	18,471
12/26/12	6.850 $	-2.42%	13,228
11/26/11	7.020 $	-3.70%	4,410
10/26/10	7.290 $	-0.95%	41,842
09/26/09	7.360 $	+6.51%	56,514

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.910USD

Average target price

16.00USD

Spread / Average Target

+131.55%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
6.910 ^USD	+0.88%		0.00%	+0.14%

10/02	ImageneBio, Inc. Appoints Ben Porter-Brown as Chief Medical Officer, Effective February 16, 2026	CI
19/12	ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025	CI

Capitalization	7.36Cr 6.2Cr 5.66Cr 5.4Cr 10Cr 666.59Cr 10Cr 66Cr 26Cr 321.91Cr 28Cr 27Cr 1.13TCr	P/E ratio 2025 *	-1.73x	P/E ratio 2026 *	-1.75x
Enterprise value	7.36Cr 6.2Cr 5.66Cr 5.4Cr 10Cr 666.59Cr 10Cr 66Cr 26Cr 321.91Cr 28Cr 27Cr 1.13TCr	EV / Sales 2025 *	276x	EV / Sales 2026 *	-
Free-Float	89.5%	Yield 2025 *	-	Yield 2026 *	-

10/02	ImageneBio, Inc. Appoints Ben Porter-Brown as Chief Medical Officer, Effective February 16, 2026	CI
19/12	ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025	CI
25/11	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
12/11	ImageneBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025	CI
29/25/29	Miragene Inc. Announces Extension of Key Service Agreement	CI
29/25/29	Imagenebio Inc elects not to renew agreement with Miragene - SEC filing	RE
24/25/24	Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target	MT
22/25/22	ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025	CI
11/25/11	ImageneBio, Inc. Announces Resignation of Jotin Marango as Principal Financial Officer, Effective October 20, 2025	CI
11/25/11	ImageneBio, Inc. Announces Resignation of Jotin Marango as Chief Financial Officer, Effective October 20, 2025	CI
31/25/31	Imagenebio Insider Bought Shares Worth $7,999,924, According to a Recent SEC Filing	MT
26/25/26	Inmagene Biopharmaceuticals Co. Ltd. completed the acquisition of Ikena Oncology, Inc. from entities affiliated with Atlas Venture L.P., entities affiliated with OrbiMed Advisors LLC, Omega Fund VI, L.P., managed by Omega Fund Management, LLC and others in a reverse merger transaction.	CI

25/11	Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target	MT
24/25/24	Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target	MT
25/25/25	Wedbush Cuts Price Target on Ikena Oncology to $23 From $25, Keeps Neutral Rating	MT
29/24/29	HC Wainwright Adjusts Price Target on Ikena Oncology to $4 From $11, Maintains Buy Rating	MT
29/24/29	Wedbush Downgrades Ikena Oncology to Neutral From Outperform After Discontinuation of Lead Program IK-930, Adjusts PT to $2 From $8	MT

ImageneBio, Inc. Share Price

Equities

IMA

US45175G2075

Biotechnology & Medical Research

Valuation: ImageneBio, Inc.

Chart: ImageneBio, Inc.

Latest news: ImageneBio, Inc.

Analysts' recommendations: ImageneBio, Inc.

Press Releases: ImageneBio, Inc.

Quotes and Performance

Course Extremes

ETFs: ImageneBio, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

10/02	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer	GL
10/02	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer	AQ
12/11	ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team	GL
06/11	ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences	GL
28/25/28	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million	AQ

1 day	+0.88%
Current month	-7.99%
1 month	+5.02%
3 months	-15.37%
6 months	-51.34%
Current year	+0.14%

1 week	6.81	7.42
1 month	6.01	7.6
Current year	6.01	7.6
1 year	5.7	18
3 years	5.7	18
5 years	5.7	18
10 years	5.7	18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMAGENEBIO, INC.	+0.88%	0.00%	-	-	7.36Cr
LONZA GROUP AG	+4.62%	+0.73%	-12.50%	-4.72%	4.76TCr
BEONE MEDICINES AG	-0.10%	-2.22%	+49.90%	+44.95%	3.83TCr
CELLTRION, INC.	-0.21%	+8.18%	+36.90%	+61.03%	3.61TCr
IQVIA HOLDINGS INC.	-1.13%	-10.96%	-13.70%	-26.47%	2.83TCr
REVOLUTION MEDICINES, INC.	-1.05%	-1.21%	+136.81%	+277.09%	1.86TCr
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+7.58%	+14.65%	+31,531.21%	+4,130.93%	1.54TCr
EUROFINS SCIENTIFIC SE	+2.25%	-3.74%	+31.21%	-3.02%	1.37TCr
ASCENDIS PHARMA A/S	-0.82%	-2.62%	+50.14%	+93.14%	1.33TCr
IONIS PHARMACEUTICALS, INC.	-1.44%	-6.82%	+159.66%	+108.92%	1.31TCr
Average	+1.06%	-0.87%	+3,552.18%	+520.21%	2.25TCr
Weighted average by Cap.	+1.23%	-0.92%	+2,204.57%	+331.96%

	2025 *	2026 *
Net sales	3L 2L 2L 2L 4L 2.42Cr 4L 23.84L 9L 1.17Cr 10L 10L 4.08Cr	-
Net income	-6.09Cr -5.13Cr -4.68Cr -4.47Cr -8.3Cr -551.68Cr -8.62Cr -54Cr -22Cr -266.42Cr -23Cr -22Cr -931.13Cr	-7.01Cr -5.91Cr -5.39Cr -5.14Cr -9.55Cr -634.99Cr -9.92Cr -63Cr -25Cr -306.65Cr -26Cr -26Cr -1.07TCr
Net Debt	-	-